One platform for all researcher needs
AI-powered academic writing assistant
Your #1 AI companion for literature search
AI tool for graphics, illustrations, and artwork
Unlock unlimited use of all AI tools with the Editage Plus membership.
Explore Editage Plus
Audio Papers
Ask R Discovery
Translation
Auto-sync
Collaboration
Open Accesshttps://doi.org/10.1016/j.jtho.2022.07.677
Copy DOI
Export
Save
Share
Cite Journal: Journal of Thoracic Oncology |  Publication Date: Sep 1, 2022 |
 License type: publisher-specific-oa |
Affiliation: Tokyo Metropolitan Komagome Hospital
In patients with NSCLC harboring molecular alterations, the efficacy of immune checkpoint inhibitors (ICI) remains unknown. The aim of our study was to examine the efficacy of first-line ICI among patients having NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations, compared to those with driver-unknown.
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
